...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>癌と化学療法 >Pharmacokinetic modulating chemotherapy highly effective for colorectal carcinoma metastases to multiple organs
【24h】

Pharmacokinetic modulating chemotherapy highly effective for colorectal carcinoma metastases to multiple organs

机译：药物动力学调节化学疗法对于结直肠癌转移至多个器官非常有效

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

AIMS: Pharmacokinetic modulating chemotherapy (PMC) is designed to boost high serum 5-fluorouracil (5-FU) concentrations through modulation by uracil. The therapeutic efficacy of PMC and the sensitivity of metastatic lesions to 5-FU were evaluated in advanced colorectal cancer patients. METHODOLOGY: Thirteen patients with colorectal carcinoma metastases to multiple organs were enrolled. PMC was initiated with a combination of 400 mg of uracil-tegafur daily and 24-hour continuous intravenous infusion of 600 mg/m2 of 5-FU once weekly. The 5-FU dose was escalated when the disease progressed. When PR was achieved, serum 5-FU concentrations were monitored in order to evaluate the chemosensitivity of each metastatic lesion to 5-FU. RESULTS: PR in the target lesion was observed in 7 of 11, 6 of 10, 2 of 2, and 2 of 4 patients with metastatic lesions to the liver, lungs, peritoneum and lymph nodes, respectively. The area under the concentration-time curve (AUC ng x hr/ml) of the 5-FU sufficient to induce PR inpulmonary lesions, 3528 to 9684, was significantly higher than for hepatic lesions, 2413 to 6323 (p = 0.028). The median survival was 13 months. CONCLUSIONS: PMC, having a chronomodulating nature, is highly effective in treating colorectal carcinoma metastases with a superior safety profile. Pulmonary metastases are more resistant to 5-FU than hepatic metastases, as they require a higher 5-FU AUC to respond.
机译：目的：药物动力学调节化学疗法（PMC）旨在通过尿嘧啶调节来提高血清5-氟尿嘧啶（5-FU）的高浓度。在晚期大肠癌患者中评估了PMC的疗效和转移灶对5-FU的敏感性。方法：招募了十三例大肠癌转移至多个器官的患者。 PMC的开始是每天400 mg尿嘧啶-替加氟和每周一次24小时连续静脉输注600 mg / m2的5-FU。疾病进展时，5-FU剂量逐渐升高。当达到PR时，监测血清5-FU浓度以评估每个转移性病变对5-FU的化学敏感性。结果：分别在肝，肺，腹膜和淋巴结转移性病变患者中，分别有11例中的7例，10例中的2例，2例中的2例和2例中的2例观察到目标病变的PR。 5-FU浓度-时间曲线下的面积（AUC ng x hr / ml）足以诱发PR肺部病变，从3528到9684，显着高于肝脏病变的2413到6323（p = 0.028）。中位生存期为13个月。结论：PMC具有时间调节特性，以优异的安全性在治疗大肠癌转移方面非常有效。肺转移瘤比肝转移瘤对5-FU的耐药性更高，因为它们需要更高的5-FU AUC来响应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号